Source: Annual Congress 2003 - Treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Hansel, R. Engelstätter, O. Benezet, H. Kafé, H. H. Ponitz, D. Cheung, P. J. Barnes (London, United Kingdom; Konstanz, Berlin, Germany; Nimes, Saint-Quentin, France; Schiedam, The Netherlands). Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients. Eur Respir J 2003; 22: Suppl. 45, 2639

Member's Comments

No comment yet.

Related content which might interest you: Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 457s Year: 2007 Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Inhaled budesonide 800 μg once daily versus 400 μg twice daily in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001 Comparison of 800 μg once vs. 400 μg twice daily inhaled budesonide in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 49s Year: 2001 Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004 The effect of esomeprazole 40mg once or twice daily on asthma outcome Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006 Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002 Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Efficacy of esomeprazole 40 mg twice daily for 16 weeks in adults with asthma: a randomised placebo-controlled trial Source: Eur Respir J 2005; 26: Suppl. 49, 278s Year: 2005 The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 "Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice Source: Eur Respir J 2006; 28: Suppl. 50, 713s Year: 2006 A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005